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Abstract
Background: Afterload reduction with bolus enalaprilat is used by some for management of acute hypertensive heart
failure (HF) but existing data on the safety and effectiveness of this practice are limited. The purpose of this study was
to evaluate the clinical effects of bolus enalaprilat when administered to patients with acute hypertensive heart failure.
Findings: We performed an IRB-approved retrospective cohort study of patients who presented to the emergency
department of a large urban academic hospital. Patients were identified by pharmacy record and included if they
received enalaprilat intravenous (IV) bolus in the setting of acute hypertensive HF. A total of 103 patients were included.
Patients were hypertensive on presentation (systolic blood pressure [SBP] = 195.2 [SD ± 32.3] mmHg) with significantly
elevated mean NT-proBNP levels (3797.8 [SD ± 6523.2] pg/ml). The mean dose of enalaprilat was 1.3 [SD ± 0.7] mg, with
most patients (76.7%) receiving a single 1.25 mg bolus. By 3 h postenalaprilat, SBP had decreased substantially
(−30.5 mmHg) with only 2 patients (1.9%) developing hypotension. Renal function was unaffected, with no significant
change in serum creatinine by 72 h. In the 30 days post-admission, patients spent an average of 23 [SD ± 7.5] days alive
and out of hospital.
Conclusions: In this retrospective cohort of acute hypertensive HF patients, bolus IV enalaprilat resulted in a substantial
reduction in systolic BP without adverse effect.
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Introduction
Acute heart failure (AHF) can be precipitated by multiple
causes, including medication non-compliance, hyperten-
sion, acute ischemia, arrhythmias, or concurrent infection
[1–3]. Regardless of the cause, patients with AHF experi-
ence an acute change in signs and symptoms requiring
urgent intervention and potential hospitalization [2].
Furthermore, AHF carries significant mortality, with an
estimated risk of in-hospital death of 4% [4], and morbidity,
with a rate of hospital readmission of ≥ 50% in the 6 months
following a first hospitalization [5–7].
Current therapies for AHF are determined based on
clinical presentation [8]. Treatment guidelines from the
American Heart Association recommend the use of IV
loop diuretics and vasodilators to reduce pulmonary
congestion [1, 3, 9]. It has been well documented that
angiotensin-converting enzyme (ACE) inhibitors are
effective in the treatment of hypertension and chronic
HF [10–14]. Enalaprilat is a parenteral ACE Inhibitor
and is the active metabolite of the orally administered
pro-drug, enalapril [10, 15]. Enalaprilat has the potential
to produce symptomatic improvement in AHF by its rapid
hemodynamic effects, particularly when blood pressure
(BP) is markedly elevated [16–18].
While afterload reduction with bolus enalaprilat is used
by some for management of AHF with hypertension in
the emergency department (ED), existing data on the
safety and effectiveness of this practice are limited
[11, 19]. However, there is real potential for delayed com-
plications as the peak BP response may not occur for up
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to 4 h after initial dosing [19]. Further, excretion is
biphasic with an early renal clearance (elimination half-life
between 2 to 6 h) and an ensuing prolonged terminal
phase (elimination half-life of 36 h) [19]. Accordingly, the
purpose of this study was to evaluate the hemodynamic
effects and safety of bolus enalaprilat in the treatment of
patients presenting to the ED with hypertensive AHF.
Methods
This is a retrospective cohort study of patients seen in
an urban, academic, tertiary care ED in Detroit, Michigan
between January 1, 2009 and July 31, 2014. Institutional
Review Board approval (Wayne State University IRB refer-
ence # 091811MP2E) was obtained before abstracting
data. The study cohort consisted of all patients greater
than 18 years old, who presented to the ED with hyperten-
sive AHF. Patients were identified by pharmacy record
review of those who received enalaprilat by IV bolus in
the ED. Electronic medical records for each identified
patient were then reviewed, and only those for whom
IV enalaprilat was used to treat AHF were included. Eli-
gible patients could have received one or more intermittent
doses of IV enalaprilat, with or without additional diuretic
or vasodilator therapy, such as continuous nitroglycerin
infusion or IV loop diuretics.
Baseline data were compiled along with hemodynamic
response over time, and the following outcome measures
were tracked: in-hospital mortality, admission loca-
tion, length of hospital stay, and final hospital dispos-
ition. The study also analyzed the rate of endotracheal
intubation and non-invasive positive pressure ventila-
tion (NIPPV) initiated in the ED, and bolus doses of
IV loop diuretics administered in the ED. Further-
more, the study analyzed the effects of IV enalaprilat
on renal and cardiac perfusion, measured from the
estimated glomerular filtration rate (eGFR) and eleva-
tion in cardiac troponin, respectively. Serum creatin-
ine and eGFR were recorded on initial presentation to
the ED and again daily for the first 3 days of admission, if
available. Cardiac specific troponin I was recorded on
presentation to the ED, 6–8 h after presentation, and
24 h after presentation, if available. All troponin sam-
ples were analyzed using a Siemens® Dimension EXL
chemistry analyzer, and a value of ≥ 0.20 ng/mL was
considered positive. The effect of IV enalaprilat on BP
was assessed on presentation to the ED and again at
30 min, 1 h, 2 h, and 3 h post-enalaprilat administra-
tion, if available. Final disposition, such as in-hospital
mortality and discharge locations, were recorded on
discharge from the hospital. Readmissions to the hospital
and ED revisits in the 30-day period post-discharge
were assessed using the electronic medical records. The
incidences of ACE inhibitor-induced angioedema were
also evaluated.
Data were analyzed with Stata 14 using maximum
likelihood for parameter estimation. We used a mixed
effects modeling approach to examine change in systolic
blood pressure over time. We hypothesized that, for each
individual, blood pressure would be a specified function
of time along with error. This trajectory is commonly
expressed as a linear function of time containing two
unknown individual latent growth factors: an intercept
and a slope. The individual intercept parameter repre-
sented mean number blood pressure at 30 min post-
drug administration. The individual slope parameter
represented the rate of change in blood pressure over
time, up to 180 min post-drug administration. Since the
number of observations per individual was relative, we
employed a linear individual growth model, rather than
including a cubic or quadratic term. After an individual
growth trajectory model is specified at Level-1 to repre-
sent the individual change over time, a Level-2 model
can be specified in which covariates or predictor vari-
ables thought to be related to or hypothesized to affect
the individual growth parameters are entered into the
model. Hospital and intensive care unit length of stay
and IV enalaprilat doses were compared using an un-
paired t test. Rates of endotracheal intubation and NIPPV
were compared using Fisher’s exact test. The study was
approved by the Wayne State University Human Inves-
tigations Committee prior to initiation. All data were
abstracted according to previously published guidelines
by Gilbert and colleagues [20] using a standardized data
collection form and specifically trained chart abstractors.
Findings
Demographics
A total of 103 patients were included, all of whom
received at least one dose of bolus enalaprilat. The mean
age was 63 years (SD± 14) with 61% male and 96% African
Americans. Tables 1 and 2 show medical history and home
medications at the time of ED presentation.
ED course and treatment
Patients were markedly hypertensive on presentation
(systolic blood pressure = 195.2 [SD ± 32.3] mmHg) with
significantly elevated NT-proBNP levels (3797.8 [SD ±
6523.2] pg/ml). The mean left ventricular ejection
fraction (LVEF) was 38% (SD ± 19). 88.3% of patients
received IV furosemide with a mean dose of 64.1 (SD ±
29.5) mg. High dose nitroglycerin (2 mg IV bolus) was
given in 13.5% of the patients. A second dose of 2 mg IV
bolus was given to 6.7% of the patients, with only 1 patient
(0.97%) receiving a third dose of 2 mg IV bolus. Continu-
ous nitroglycerin IV infusion was started in 21.3% of
patients, with 18.4% receiving an initial drip at 50 mcg/
min, and 2.9% receiving 100 mcg/min.
Ayaz et al. International Journal of Emergency Medicine  (2016) 9:28 Page 2 of 7
The mean time to enalaprilat administration in the ED
after presentation was 121.5 min (SD ± 144.9). The mean
dose of enalaprilat was 1.3 (SD ± 0.7) mg, with most
patients (77.7%) receiving a single 1.25 mg bolus. By 3 h
postenalaprilat, systolic blood pressure (BP) had decreased
substantially (−30.5 mmHg) with only 2 patients (1.9%)
developing hypotension (systolic BP < 90 mmHg).
Figures 1, 2, 3, 4, 5 depict vital signs at baseline and
30, 60, 120, and 180 min after enalaprilat administration.
In our initial model, only the intercept was allowed to
vary. The fixed effect of time was statistically significant,
p = 0.0001: SBP decreased by a mean of 8.67 mmHg over
each of the four time periods. In addition, the intercept
contained significant variability (p = 0.0001) available for
prediction in the Level-2 model. The second model, in
which both the intercept and slope were allowed to vary,
did not provide improved model fit compared to the
simpler intercept-only model. In other words, there
was evidence that participants showed significant vari-
ability at the beginning of treatment but reduction in
SBP over time was consistent across people. We then
attempted to explain changes in SBP by entering ex-
planatory covariates into our model: time, age, gender,
admission SBP, admission GFR, and total amount of
enalaprilat given. As in our intercept-only model, time
was statistically significant. Admission SBP was also
significant, which is not surprising: the higher the
admission SBP, the higher it was over time. The remaining
covariates were not significant, including the total amount
of enalaprilat given. However, there was limited explana-
tory variance in this variable, i.e., over 75% of participants
were given the same dose of the medication.
We also used a mixed effects model with a random
intercept to examine the impact of enalaprilat plus nitro-
glycerin versus enalaprilat alone on SBP. This group
variable was entered into the model while controlling for
age, gender, admission SBP, and admission GFR. The time/
period effect was significant with an average reduction in
SBP of over 8 mmHg with each period. As with our other
models, admission SBP remained significant. While there
was not a statistically significant difference/effect of added
nitroglycerin (p = 0.18), patients who received nitroglycerin
had about a 7-point lower SBP than those who received
enalaprilat alone.
Most (80.6%) patients had a troponin concentration
obtained during their initial ED admission, which was
positive in 58.1%. Fewer patients had a troponin drawn
at 6–8 h (59.2%) or 24 h (45.6%) post-admission, only
9% of which were positive. Serum BUN, creatinine, and
glomerular filtration rate were largely unaffected with no
significant change by 72 h (Table 3). Only 7.8% were
placed on NIPPV and 3.9% required endotracheal intub-
ation. No patient developed angioedema during or post-
treatment.
Disposition
Nearly one third (30.1%) of patients were admitted to
the ICU; 27.2% were admitted to a telemetry floor bed,
35.0% were admitted to observation unit, and 7.7% ad-
mitted to the regular medical floor. The mean (SD)
length of hospital stay was 4.6 (4.1) days, with a mean
standard deviation ICU length of stay of 2.6 (1.7) days.
After the hospital stay, the majority of patients (85.7%)
were discharged home; 7 patients were sent to long-
term care facilities, and 2 were sent to rehabilitation
centers. There were no patients who died in hospital.
In the 30 days after admission, patients spent an aver-
age of 23 (SD ± 7.5) days out of hospital and alive.
Discussion
Data from our retrospective cohort show a substantial
decrease in SBP (−30.5 mmHg) within 3 h postenalaprilat
administration. Although relatively small, evidence from
previous clinical trials suggests that enalaprilat is generally
Table 1 Past medical history




Intravenous drug user 5.8%
Diabetes mellitus type II 27.1%
Chronic obstructive pulmonary disease 16.5%
Asthma 12.6%
Chronic kidney disease 15.5%
End stage renal disease (on hemodialysis) 5.8%




Coronary artery disease 5.8%
Table 2 Home medications
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Fig. 1 Systolic blood pressure at baseline and after enalaprilat administration
Fig. 2 Diastolic blood pressure at baseline and after enalaprilat administration
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well tolerated [11]. Our findings support this, with no
evidence of adverse effects on renal function or cardiac
perfusion, and no evidence of excess in-hospital mortality
or post-discharge recidivism. The most plausible con-
cern with an IV bolus administration of enalaprilat is
hypotension [11]. However, we found few episodes of
hypotension in our patient population suggesting that
IV enalaprilat is safe for administration in the setting of
hypertensive AHF. Additionally, while 96% of our study
cohort was African American, no patients experienced
Fig. 3 Heart rate at baseline and after enalaprilat administration
Fig. 4 Respiratory rate at baseline and after enalaprilat administration
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ACE inhibitor-induced angioedema, suggesting that any
concerns for acute onset of this well-known side effect
are unfounded.
Traditionally IV diuretics have been used in the early
management of patients presenting with AHF in the ED
[11]. However, the latest evidence suggests that there is
a particular phenotype of HF patients that present to the
ED with acute hypertension and can be managed more
appropriately with IV vasodilators as an adjunct to diur-
etic therapy [21–24]. The American Heart Association,
in its 2013 practice guidelines, recommended nitrovaso-
dilators and nesiritide in hospitalized hypertensive HF
patients (class IIb, level of evidence A) [3]. Although IV
vasodilators are increasingly being used in the ED set-
ting, a recent systematic review of existing literature
found a lack of evidence and clinical experience for
the use IV enalaprilat in ED patients with acute hyper-
tensive HF. [11] Our data add to the existing evidence
base, providing treatment response and outcome data
for the largest cohort to date who were treated with
IV enalaprilat in the setting of hypertensive AHF.
Limitations
The primary limitation of this study was its retrospective
nature. While this precludes the ability to capture relevant
clinical information on all patients in a uniform manner, we
were able to compile outcome data on all subjects and
repeat measure data on a reasonable proportion, thus yield-
ing sufficient information to base effect size estimation for
potential future studies. As well, the sample size itself is
relatively small; however, this reflects the pragmatic design
of our study and all patients who received IV enalaprilat
during the study period were included. Although the
number of patients at our institution who received IV
enalaprilat may seem low (approximately 20 patients
per year over the study period), our approach to case
ascertainment using pharmacy records makes it un-
likely that we missed any patients who were treated in
Fig. 5 Pulse oximetry at baseline and after enalaprilat administration
Table 3 Renal function at presentation and during index hospitalization
ED presentation Day 1 Day 2 Day 3
n = 103 n = 83 n = 70 n = 64
Serum BUN (mg/dL) 23.7 [SD ± 14.1] 25.7 [SD ± 16.4] 26.2 [SD ± 14.1] 28.0 [SD ± 16.8]
Serum creatinine (mg/dL) 2.39 [SD ± 4.35] 2.16 [SD ± 2.0] 2.0 [SD ± 1.5] 2.2 [SD ± 1.9]
GFR (mL/min/1.73 m2) 59.5 [SD ± 30.3] 59.2 [SD ± 30.0] 59.0 [SD ± 29.0] 57.2 [SD ± 31.9]
SD standard deviation; BUN blood urea nitrogen; GFR glomerular filtration rate
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this manner. Symptom (dyspnea) relief is an important
outcome to report in any study investigating AHF treat-
ment in the ED. However, time to symptom relief is not
documented consistently in patients’ charts (electronic
medical records) for accurate retrospective analysis. In
addition, patients did receive other concurrent antihy-
pertensive therapy which could have confounded noted
effects on BP and other measures. Future studies are
clearly warranted to see if enalaprilat offers any specific
advantages over other interventions, and our data has
utility for the design of such trials.
Conclusions
In this retrospective cohort study, use of bolus IV ena-
laprilat was well tolerated, resulting in a substantial
reduction in systolic BP with limited hypotension and
no adverse effect on renal function when administered
to hypertensive patients with AHF. While prospective
comparison trials are needed, these data suggest a potential
role for bolus IV enalaprilat in the management of
hypertensive AHF.
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